Advertisement

Central European Journal of Medicine

, Volume 5, Issue 6, pp 659–665 | Cite as

EMMPRIN and fascin expression in non-small cell lung carcinoma

  • Mehmet Kefeli
  • Aysen Taslak Sengul
  • Levent Yildiz
  • Sancar Baris
  • Ahmet Basoglu
  • Bedri Kandemir
Research Article

Abstract

Fascin and EMMPRIN (CD 147) have a demonstrated relationship with the invasion and progression of many tumors. The aim of this study was to analyze fascin and EMMPRIN expression in non-small cell lung carcinoma and their relationship with clinicopathologic features. Fascin and EMMPRIN expression levels were investigated via the immunohistochemistry of paraffin-embedded tissues of 64 patients with non-small cell lung carcinoma, including 46 squamous cell carcinoma and 18 adenocarcinoma patients. The patients were scored on the basis of staining extent and intensity, and were then assigned a combined score. Fascin expression was present in 44 of 46 (95.6%) patients with SCC and 16 of 18 (88.8%) patients with adenocarcinoma. There was a significant correlation between fascin expression and tumor stage in the SCC and adenocarcinoma groups. EMMPRIN expression was observed in all patients with SCC (46 of 46, 100%) and 16 of 18 (88.8%) patients with adenocarcinoma. There was significant correlation between EMMPRIN expression and both tumor stage and diameter in the SCC group, but not in the adenocarcinoma group. This study revealed that high levels of fascin and EMMPRIN expression may indicate the importance of their roles in the progression of non-small cell lung carcinoma and they could be used as prognostic marker for these tumors.

Keywords

Fascin EMMPRIN CD 147 Lung carcinoma Non-small cell 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J., Cancer statistics, CA Cancer J. Clin., 2008, 58, 71–96CrossRefPubMedGoogle Scholar
  2. [2]
    Husain A.N., The Lung, In: Kumar V., Abbas A.K., Fausto N., Aster J.C. eds. Robbins and Cotran Pathologic Basis of Disease. Eighth Edition, Philadelphia, Saunders Elsevier, 2010, 677–737Google Scholar
  3. [3]
    Bepler G., Goodridge Carney D., Djulbegovic B., Clark R.A., Tockman M., A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest, Cancer Control 2003, 10, 306–14PubMedGoogle Scholar
  4. [4]
    Al-Saad S., Al-Shibli K., Donnem T., Persson M., Bremnes R.M., Busund L.T., The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer, Br. J. Cancer, 2008, 99, 1476–83CrossRefPubMedGoogle Scholar
  5. [5]
    Nakashima M., Ohike N., Nagasaki K., Adachi M., Morohoshi T., Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma, J. Cancer Res. Clin. Oncol., 2004, 130, 475–9CrossRefPubMedGoogle Scholar
  6. [6]
    Perner S., Wagner P.L., Soltermann A., LaFargue C., Tischler V., Weir B.A., Weder W., Meyerson M., Giordano T.J., Moch H., Rubin M.A., TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival, J. Pathol., 2009, 217, 65–72CrossRefPubMedGoogle Scholar
  7. [7]
    Pelosi G., Barisella M., Pasini F., Leon M.E., Veronesi G., Spaggiari L., Fraggetta F., Iannucci A., Masullo M., Sonzogni A., Maffini F., Viale G., CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients, Mod. Pathol., 2004, 17, 711–21CrossRefPubMedGoogle Scholar
  8. [8]
    Hirabayashi H., Ohta M., Tanaka H., Sakaguchi M., Fujii Y., Miyoshi S., Matsuda H., Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53, J. Surg. Oncol., 2002, 81, 177–84CrossRefPubMedGoogle Scholar
  9. [9]
    Sun J., Hemler M.E., Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions, Cancer Res., 2001, 61, 2276–81PubMedGoogle Scholar
  10. [10]
    Muramatsu T., Miyauchi T., Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion, Histol. Histopathol, 2003, 18, 981–7PubMedGoogle Scholar
  11. [11]
    Shapiro S.D., Matrix metalloproteinase degradation of extracellular matrix: biological consequences, Curr. Opin. Cell Biol., 1998, 10, 602–8CrossRefPubMedGoogle Scholar
  12. [12]
    Chambers A.F., Matrisian L.M., Changing views of the role of matrix metalloproteinases in metastasis, J. Natl. Cancer Inst., 1997, 89, 1260–70CrossRefPubMedGoogle Scholar
  13. [13]
    Riethdorf S., Reimers N., Assmann V., Kornfeld J.W., Terracciano L., Sauter G., Pantel K., High incidence of EMMPRIN expression in human tumors, Int. J. Cancer 2006, 119, 1800–10CrossRefPubMedGoogle Scholar
  14. [14]
    Tsai W.C., Chao Y.C., Sheu L.F., Lin Y.F., Nieh S., Chen A., Yu C.P., Jin J.S., EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people, APMIS, 2007, 115, 929–38CrossRefPubMedGoogle Scholar
  15. [15]
    Zheng H.C., Takahashi H., Murai Y., Cui Z.G., Nomoto K., Miwa S., Tsuneyama K., Takano Y., Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis, Br. J. Cancer, 2006, 95, 1371–8CrossRefPubMedGoogle Scholar
  16. [16]
    Tsai W.C., Chao Y.C., Lee W.H., Chen A., Sheu L.F., Jin J.S., Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters, Histopathology, 2006, 49, 388–95CrossRefPubMedGoogle Scholar
  17. [17]
    Han Z.D., He H.C., Bi X.C., Qin W.J., Dai Q.S., Zou J., Ye Y.K., Liang Y.X., Zeng G.H., Zhu G., Chen Z.N., Zhong W.D., Expression and clinical significance of CD147 in genitourinary carcinomas, J. Surg. Res., 2008, (In press)Google Scholar
  18. [18]
    De Arcangelis A., Georges-Labouesse E., Adams J.C., Expression of fascin-1, the gene encoding the actin-bundling protein fascin-1, during mouse embryogenesis, Gene Exp. Patt., 2004, 4, 637–43CrossRefGoogle Scholar
  19. [19]
    Hashimoto Y., Skacel M., Adams J.C., Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker?, Int. J. Biochem. Cell Biol., 2005, 37, 1787–804CrossRefPubMedGoogle Scholar
  20. [20]
    Kureishy N., Sapountzi V., Prag S., et al, Fascins, and their roles in cell structure and function, Bioessays, 2002, 24, 350–61CrossRefPubMedGoogle Scholar
  21. [21]
    Pelosi G., Pastorino U., Pasini F., et al, Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer, Br. J. Cancer, 2003, 88, 537–47CrossRefPubMedGoogle Scholar
  22. [22]
    Peraud A., Mondal S., Hawkins C., et al, Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades, Brain Tumor Pathol., 2003, 20, 53–8CrossRefPubMedGoogle Scholar
  23. [23]
    Rodriguez-Pinilla S.M., Sarrio D., Honrado E., et al, Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res, 2006, 12, 1533–39CrossRefPubMedGoogle Scholar
  24. [24]
    Tong G.X., Yee H., Chiriboga L., et al, Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder, Hum. Pathol., 2005, 36, 741–6CrossRefPubMedGoogle Scholar
  25. [25]
    Grothey A., Hashizume R., Sahin A.A., et al, Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer, Br. J. Cancer, 2000, 83, 870–73CrossRefPubMedGoogle Scholar
  26. [26]
    Hashimoto Y., Shimada Y., Kawamura J., et al, The prognostic relevance of fascin expression in human gastric carcinoma, Oncology, 2004, 67, 262–70CrossRefPubMedGoogle Scholar
  27. [27]
    Pelosi G., Pastorino U., Pasini F., Maissoneuve P., Fraggetta F., Iannucci A., Sonzogni A., De Manzoni G., Terzi A., Durante E., Bresaola E., Pezzella F., Viale G., Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer, Br. J. Cancer, 2003, 88, 537–47CrossRefPubMedGoogle Scholar
  28. [28]
    Choi P.J., Yang D.K., Son C.H., Lee K.E., Lee J.I., Roh M.S., Fascin immunoreactivity for preoperatively predicting lymph node metastases in peripheral adenocarcinoma of the lung 3 cm or less in diameter, Eur. J. Cardiothorac Surg, 2006, 30, 538–42CrossRefPubMedGoogle Scholar
  29. [29]
    Hakuma N., Betsuyaku T., Kinoshita I., Itoh T., Kaga K., Kondo S., Nishimura M., Dosaka-Akita H., High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters, Oncology, 2007, 72, 197–204CrossRefPubMedGoogle Scholar
  30. [30]
    Sienel W., Polzer B., Elshawi K., Lindner M., Morresi-Hauf A., Vay C., Eder F., Passlick B., Klein CA., Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9, Mod. Pathol., 2008, 21, 1130–8CrossRefPubMedGoogle Scholar
  31. [31]
    Travis W.D., Brambilla E., Muller-Hermelink K.H., Harris C.C., Pathology and genetics of tumours of the lung, pleura, thymus and heart, IARC Press, Lyon 2004, p. 9–124Google Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Mehmet Kefeli
    • 1
  • Aysen Taslak Sengul
    • 1
  • Levent Yildiz
    • 1
  • Sancar Baris
    • 1
  • Ahmet Basoglu
    • 1
  • Bedri Kandemir
    • 1
  1. 1.Ondokuz Mayis UniversitySamsunTurkey

Personalised recommendations